Search

Your search keyword '"Ruiz-Delgado, Guillermo José"' showing total 22 results
Start Over Author "Ruiz-Delgado, Guillermo José" Publication Year Range Last 10 years
22 results on '"Ruiz-Delgado, Guillermo José"'

2. Prevalence of the t(11; 14)(q13; q32) immunoglobulin H/CCND1 in Mexican mestizos with multiple myeloma: A single institution experience

Author

Lira-Lara, Olivia, primary, Gallardo-Pérez, Moisés Manuel, additional, Garcés-Eisele, Solón Javier, additional, Reyes-Núñez, Virginia Adriana, additional, López-Trujillo, Miguel Antonio, additional, Melgar-de-la-Paz, Miranda, additional, Negrete-Rodríguez, Paola, additional, Hamilton-Avilés, Luis Enrique, additional, Ocaña-Ramm, Guillermo, additional, Robles-Nasta, Max, additional, Sánchez-Bonilla, Daniela, additional, Olivares-Gazca, Juan Carlos, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz-Argüelles, Guillermo José, additional

Published
2024
Full Text
View/download PDF

3. ALL-419 Can Doses of Post-Transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Be Reduced?

Author

Olivares-Gazca, Juan Carlos, primary, de Lourdes Pastelín-Martínez, María, additional, Montes-Robles, Merittzel Abigail, additional, Gallardo-Pérez, Moisés Manuel, additional, Hernández-Flores, Edgar Jared, additional, Robles-Nasta, Max, additional, Sánchez-Bonilla, Daniela, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz-Argüellez, Guillermo José, additional

Published
2023
Full Text
View/download PDF

4. POSTER: ALL-422 Therapy of Childhood Acute Lymphoblastic Leukemia (ALL) in Resource-Poor Geospaces

Author

Gallardo-Pérez, Moisés Manuel, primary, Gale, Robert Peter, additional, Reyes-Cisneros, Oscar A., additional, Sánchez-Bonilla, Daniela, additional, Fernández-Gutiérrez, José A., additional, Stock, Wendy, additional, Murrieta-Álvarez, Iván, additional, Olivares-Gazca, Juan Carlos, additional, Nasta, Max Robles, additional, Ruiz-Delgado, Guillermo José, additional, Fonseca, Rafael, additional, and Ruiz-Argüelles, Guillermo José, additional

Published
2023
Full Text
View/download PDF

5. POSTER: CML-416 Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelogenous Leukemia in the Tyrosine-Kinase Inhibitors Era: A Single Institution Experience

Author

Robles-Nasta, Max, primary, Sánchez-Bonilla, Daniela, additional, Gallardo-Pérez, Moisés Manuel, additional, Hernández-Flores, Edgar Jared, additional, Montes-Robles, Merittzel Abigail, additional, de Lourdes Pastelín-Martínez, María, additional, Olivares-Gazca, Juan Carlos, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz-Argüellez, Guillermo José, additional

Published
2023
Full Text
View/download PDF

6. POSTER: ALL-419 Can Doses of Post-Transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Be Reduced?

Author

Olivares-Gazca, Juan Carlos, primary, de Lourdes Pastelín-Martínez, María, additional, Montes-Robles, Merittzel Abigail, additional, Gallardo-Pérez, Moisés Manuel, additional, Hernández-Flores, Edgar Jared, additional, Robles-Nasta, Max, additional, Sánchez-Bonilla, Daniela, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz-Argüellez, Guillermo José, additional

Published
2023
Full Text
View/download PDF

7. CML-416 Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelogenous Leukemia in the Tyrosine-Kinase Inhibitors Era: A Single Institution Experience

Author

Robles-Nasta, Max, primary, Sánchez-Bonilla, Daniela, additional, Gallardo-Pérez, Moisés Manuel, additional, Hernández-Flores, Edgar Jared, additional, Montes-Robles, Merittzel Abigail, additional, de Lourdes Pastelín-Martínez, María, additional, Olivares-Gazca, Juan Carlos, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz-Argüellez, Guillermo José, additional

Published
2023
Full Text
View/download PDF

8. ALL-422 Therapy of Childhood Acute Lymphoblastic Leukemia (ALL) in Resource-Poor Geospaces

Author

Gallardo-Pérez, Moisés Manuel, primary, Gale, Robert Peter, additional, Reyes-Cisneros, Oscar A., additional, Sánchez-Bonilla, Daniela, additional, Fernández-Gutiérrez, José A., additional, Stock, Wendy, additional, Murrieta-Álvarez, Iván, additional, Olivares-Gazca, Juan Carlos, additional, Nasta, Max Robles, additional, Ruiz-Delgado, Guillermo José, additional, Fonseca, Rafael, additional, and Ruiz-Argüelles, Guillermo José, additional

Published
2023
Full Text
View/download PDF

9. Long-Term Results of the Treatment of Adolescents and Adults with Acute Lymphoblastic Leukemia with a Pediatric-Inspired Regimen Delivered on an Outpatient Basis: A Single Institution Experience

Author

García-Villaseñor, Elizabeth, primary, Cortes, Jorge E., additional, Reyes-Cisneros, Oscar A., additional, Fernández-Gutiérrez, José Antonio, additional, Sánchez-Bonilla, Daniela, additional, Bojalil-Álvarez, Lorena, additional, Murrieta-Álvarez, Iván, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz Argüelles, Guillermo José, additional

Published
2022
Full Text
View/download PDF

10. Patient-Reported-Outcomes and Safety of Autologous Stem Cell Transplantation in Multiple Sclerosis: A Single Center Experience with the "Mexican Method" in 1300 Persons

Author

Olivares-Gazca, Juan Carlos, primary, Sánchez-Bonilla, Daniela, additional, Fernández-Gutiérrez, José Antonio, additional, Reyes-Cisneros, Oscar A., additional, Gallardo-Pérez, Moisés Manuel, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz-Argüelles, Guillermo José, additional

Published
2022
Full Text
View/download PDF

11. Long-term results of the treatment of Hodgkin’s lymphoma in a resource-constrained setting: Real-world data from a single center

Author

Sánchez-Valledor, Luisa Fernanda, primary, Habermann, Thomas M, additional, Murrieta-Alvarez, Iván, additional, Córdova-Ramírez, Alejandra Carmina, additional, Rivera-Álvarez, Montserrat, additional, León-Peña, Andrés, additional, Cantero-Fortiz, Yahveth, additional, Olivares-Gazca, Juan Carlos, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz-Argüelles, Guillermo José, additional

Published
2021
Full Text
View/download PDF

12. Autologous HSCT for Multiple Sclerosis Should be Done Early in the Course of the Disease

Author

Pastelín-Martínez, María de Lourdes, Gallardo-Pérez, Moisés Manuel, Gomez-De Leon, Andres, Olivares-Gazca, Juan Carlos, Hernández-Flores, Edgar Jared, Sánchez-Bonilla, Daniela, Montes-Robles, Merittzel Abigail, Robles-Nasta, Max, Ocaña-Ramm, Guillermo, Soto-Olvera, Silvia, Gomez-Almaguer, David, Ruiz-Delgado, Guillermo José, and Ruiz-Arguelles, Guillermo José

Published
2023
Full Text
View/download PDF

13. Up to half of patients diagnosed with chronic lymphocytic leukemia in México may not require treatment

Author

Cruz-Mora, Antonio, primary, Murrieta-Alvarez, Iván, additional, Olivares-Gazca, Juan Carlos, additional, León-Peña, Andrés, additional, Cantero-Fortiz, Yahveth, additional, García-Navarrete, Yarely Itzayana, additional, Sánchez-Valledor, Luisa Fernanda, additional, Khalaf, Dina, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz-Argüelles, Guillermo José, additional

Published
2020
Full Text
View/download PDF

14. Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data from a Single Institution

Author

Murrieta-Álvarez, Iván , primary, Steensma, David P., additional, Olivares-Gazca, Juan Carlos, additional, Olivares-Gazca, Mauricio, additional, León-Peña, Andrés, additional, Cantero-Fortiz, Yahveth, additional, García-Navarrete, Yarely Itzayana, additional, Cruz-Mora, Antonio, additional, Ruiz-Argüelles, Alejandro, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz-Argüelles, Guillermo José, additional

Published
2020
Full Text
View/download PDF

15. Determine safety of outpatient chemotherapy and autotransplants using refrigerated, non‐frozen grafts in persons with multiple sclerosis

Author

Gale, Robert Peter, primary, Gómez‐Cruz, Gisela Berenice, additional, Olivares‐Gazca, Juan Carlos, additional, León‐Peña, Andrés A., additional, Gómez‐Almaguer, David, additional, Gómez‐De‐León, Andrés, additional, González‐López, Elías Eugenio, additional, Ruiz‐Argüelles, Alejandro, additional, Soto‐Vega, Elena, additional, Muñoz‐Pérez, María José, additional, Ruiz‐Delgado, Guillermo José, additional, and Ruiz‐Argüelles, Guillermo José, additional

Published
2019
Full Text
View/download PDF

16. Health-Related Quality of Life in leukemia Survivors of Allogeneic Hematopoietic Stem Cell Transplantation Employing the Mexican Reduced-Intensity Conditioning

Author

González Ramírez, Mónica P., Miravete Lagunes, Karla, Gómez de León, Andrés, Ponce de León, Sergio, Tenorio Rojo, Andrea P., Martagón Herrera, Nora A., Hérnandez Reyes, Jésus A., García Villaseñor, Arturo, Burguette, Esteban, Vallejo Villalobos, María Fernanda, Ruiz Delgado, Guillermo José, Gómez Almaguer, David, Ruiz Argüelles, Guillermo José, González Ramírez, Mónica P., Miravete Lagunes, Karla, Gómez de León, Andrés, Ponce de León, Sergio, Tenorio Rojo, Andrea P., Martagón Herrera, Nora A., Hérnandez Reyes, Jésus A., García Villaseñor, Arturo, Burguette, Esteban, Vallejo Villalobos, María Fernanda, Ruiz Delgado, Guillermo José, Gómez Almaguer, David, and Ruiz Argüelles, Guillermo José

Abstract

Background: Quality of life (QOL) is an important consideration in the counseling, implementation, and post-treatment management of arduous treatments for life-threatening conditions such as allogeneic hematopoietic cell transplantation (allo-HCT). Objective: To analyze the QOL of leukemia patients allografted with the Mexican reduced-intensity conditioning regimen in two Mexican academic medical centers. Material and methods: By means of the quality metric short form 36 version 2 to measure generic health concepts, relevant QOL was analyzed in leukemia patients who underwent allo-HCT using reducedintensity conditioning on an outpatient basis at either the Centro de Hematología y Medicina Interna de Puebla of the Clínica Ruiz or the Hematology Service of the Internal Medicine Department of the Hospital “Dr. José Eleuterio González” of the Universidad Autónoma de Nuevo León, and who had survived more than 12 months after the allograft, who could be approached, who were in a continued complete remission (with or without graft-versus-host disease), and who were willing to respond to the questionnaire. Thirty-five patients fulfilling these requirements were included, and a sex- and age-matched group of 35 reference subjects was also studied. Results: Allografted patients were found to have a slightly better mental component summary than the reference subjects (53.23 vs. 48.66 points; p = 0.01), whereas the physical component summary did not show a difference (54.53 vs. 52.05 points; p = 0.59). Most of the differences between allografted individuals and reference subject controls were not significant. Conclusions: Despite several sources of bias, these data suggest that allografted individuals employing the Mexican reduced-intensity conditioning regimen enjoy a health-related QOL life similar to that of reference subjects, adding another advantage of this method of conducting stem cell allografts. However, more work needs to be done to elucidate the impact of reduced-int

Published
2015

18. The Doses of Post-Transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Can be Reduced

Author

Olivares-Gazca, Juan Carlos, Pastelín-Martínez, María de Lourdes, Montes-Robles, Merittzel Abigail, Gallardo-Pérez, Moisés Manuel, Hernández-Flores, Edgar Jared, Robles-Nasta, Max, Sánchez-Bonilla, Daniela, Gutierrez-Aguirre, César Homero, Gomez-De Leon, Andres, Gomez-Almaguer, David, Ruiz-Delgado, Guillermo José, and Ruiz-Arguelles, Guillermo José

Abstract

Background

Published
2023
Full Text
View/download PDF

20. Secondary malignancies after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and outpatient conduction.

Author

Zamora-Ortiz, Gabriela, Velázquez-Sánchez-de-Cima, Sara, Ponce-de-León, Sergio, Gutiérrez-Aguirre, César Homero, Ruiz-Delgado, Guillermo José, Gomez-Almaguer, David, and Ruiz-Argüelles, Guillermo José

Subjects
STEM cell transplantation research, THERAPEUTIC complications, HEALTH outcome assessment, HEMATOLOGY, CANCER research
Abstract

Background: Patients given allogeneic hematopoietic stem cell transplants (HSCT) may develop secondary malignant neoplasms (SMN). Several variables have been identified but there are no data about the incidence of this complication in individuals given HSCT using reduced-intensity conditioning (RIC) methods. Objective: Define the incidence of SMN in patients given HSCT using a RIC preparative regimen conducted on an outpatient basis. Materials and methods: Patients given HSCT in two institutions between October 1998 and 2012 were analyzed. To appraise the SMN appearance, those patients dead were also regarded as censored at that moment, as well as those lost to follow up and those alive at the closing of the study. 95% Confidence intervals (CI) for the survival or failure estimate were calculated with the Greenwood’s method. Results: A total of 416 allografted patients with a Karnofsky performance index of 100% were included in the study. All patients received peripheral blood stem cells allografts. The conditioning regimen was delivered as an outpatient procedure in all individuals. No patient was given radiotherapy nor antithymocyte globulin during the conditioning. Three hundred and sixty five patients (88%) were never admitted to the hospital, whereas 12% were admitted because of grade III–IV acute graft versus host disease (aGVHD), fever, or mucositis. Median survival time was 15.7 months. Survival at 6 months (95% CI): 66.4% (61.5–70.8%), at 12 months: 53.3% (48.1–58.1%), at 60 months: 30.6% (30.5–41.5%). Eight patients with a SMN were identified in the group of 416 allografted patients, SMN rates (95% CI) were: one year post graft: 1.9% (0.7–4.9%), 5 years: 3.8% (1.6–9.2%), 10 years: 6.8% (2.6–17.7%) and 13 years post-graft: 20.2% (5.5–59.2%), the cumulative probability of SMN being 6.8 at 10 years. Since the number of expected cases in the general population is 0.62, the ratio of observed to expected cases is 12.9 (P < 0.001). This figure means that the risk of developing a malignant neoplasm in allografted individuals using our method is 12.9 times higher than that in the general population. There were three non-Hodgkin’s lymphomas, two M2 acute myelogenous leukemias, one hairy cell leukemia, one tongue epidermoid carcinoma, and one breast carcinoma. Conclusions: We have found a low incidence of SMN in this group of Mexican patients allografted with the Mexican RIC method. Possible explanations for this difference are discussed, focusing on the RIC preparative regimen. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

21. [Reporte de la Primera Reunión Nacional de Consenso para la Inmunofenotipificación de Leucemias Agudas].

Author

Arriaga-Pizano L, Ramírez-Ramírez D, Prieto-Chávez J, Pelayo R, Ruiz-Argüelles A, Ruiz-Delgado GJ, and Marín y López RA

Subjects
Guideline Adherence, Hematologic Neoplasms immunology, Humans, Laboratories standards, Latin America, Leukemia immunology, Hematologic Neoplasms diagnosis, Immunophenotyping methods, Leukemia diagnosis
Abstract

En 2005 se publicaron recomendaciones para la tipificación de hemopatías malignas en Latinoamérica. Se consideró necesario realizar una reunión nacional para actualizarlas. Se convocaron y reunieron 95 profesionales expertos en el tema para analizar y contrastar alternativas y llegar a un consenso. Se alcanzaron opiniones de consenso en lo relativo a indicaciones, tipos y manejo de muestras, anticuerpos, nomenclatura e informe de resultados para el diagnóstico y seguimiento de las leucemias agudas. Las recomendaciones se describen en este artículo y se hace hincapié en la necesidad de que los laboratorios nacionales se apeguen a ellas., (Copyright: © 2019 SecretarÍa de Salud.)

Published
2019
Full Text
View/download PDF

22. IKAROS Gene Deleted B-Cell Acute Lymphoblastic Leukemia in Mexican Mestizos: Observations in Seven Patients and a Short Review of the Literature.

Author

Ruiz-Delgado GJ, Cantero-Fortiz Y, León-Peña AA, León-González M, Nuñez-Cortés AK, and Ruiz-Argüelles GJ

Subjects
Adolescent, Female, Follow-Up Studies, Humans, Indians, North American genetics, Male, Mexico, Middle Aged, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology, Prognosis, Prospective Studies, Survival Rate, Young Adult, Gene Deletion, Ikaros Transcription Factor genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics
Abstract

Background: In B-cell acute lymphoblastic leukemia, one of the most frequent cytogenetic alterations is the presence of the Philadelphia chromosome. Recently, newly identified genetic alterations have been studied, among them the IKZF1 deletion. IKZF1 encodes IKAROS, a zinc finger protein that plays an important role in hematopoiesis involving the regulation process of adhesion, cellular migration, and as a tumor suppressor., Objective: We aimed to study the impact of IKAROS deletion in the evolution and prognosis of B-cell acute lymphoblastic leukemia., Materials and Methods: At a single center we prospectively studied patients diagnosed with B-cell acute lymphoblastic leukemia and screened for IKZF1 deletion using the multiplex ligation-dependent probe amplification method. We did a descriptive analysis of patients positive for the IKZF1 deletion to determine its impact on the evolution of the disease and survival rate., Results: Between 2010 and 2015, 16 Mexican mestizo patients with B-cell acute lymphoblastic leukemia were prospectively screened for IKZF1 deletion; seven (43%) were positive and were included for further analysis. The age range of patients was 13-60 years; six were males and one female. All cases had type B acute lymphoblastic leukemia. Of the seven patients, two died, three were lost to follow-up, and two continue in complete remission with treatment. Results are worse than those in a group of patients with non-mutated IKAROS B-cell acute lymphoblastic leukemia previously studied in our center., Conclusions: Although this is a small sample, the presence of IKAROS deletion in acute lymphoblastic leukemia patients could represent a poor-prognosis marker and was probably related to therapy failure. It is also possible that this variant of leukemia may be more prevalent in Mexico. More studies are needed to define the role of IKZF1 deletion in acute lymphoblastic leukemia and the real prevalence of the disease in different populations.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results